ETODOLAC, ASPIRIN, AND PLACEBO IN PATIENTS WITH RHEUMATOID-ARTHRITIS - A 12-WEEK STUDY

  • 1 January 1983
    • journal article
    • research article
    • Vol. 5  (5) , 495-503
Abstract
Etodolac, aspirin and placebo were evaluated for efficacy and safety in 18 patients with adult-onset, active rheumatoid arthritis. This was a 12-wk, double-blind, parallel-group study divided into drug titration and maintenance periods and preceded by a washout period of up to 2 wk. The mean daily maintenance doses of etodolac and aspirin were 394 mg and 4414 mg, respectively. Etodolac was significantly (P .ltoreq. 0.05) more effective than placebo in 5 of 10 clinical variables of efficacy: number of painful joints; number of swollen joints; pain intensity; erythrocyte sedimentation rate; and patients'' overall assessments. Aspirin was significantly more effective than placebo in only 2 assessments: number of painful joints and pain intensity. One patient on etodolac, 2 patients on aspirin and 4 patients on placebo had to be withdrawn from the trial because of insufficient therapeutic response. One patient in the placebo group was withdrawn from the study because of a pruritic rash. Mild to moderate gastrointestinal complaints occurred in all treatment groups: in 3 patients taking etodolac; 3 taking aspirin and 2 taking placebo.

This publication has 0 references indexed in Scilit: